Abstract
Chronic kidney disease (CKD) is a very common complication in patients with diabetes mellitus, arterial hypertension and dyslipidemia. Worldwide prevalence of CKD reaches about 15 %.
However, this estimation is biased due to frequently asymptomatic signs in early stages of the disease. Dyslipidemia is a constant metabolic complication of CKD, even from its early stages.
The patients are on higher risk for death from cardiovascular disease or complications in comparison to those without present kidney disease. One of current problems represents the modalities for influencing cardiovascular risk.
Hypolipidemic therapy is unequivocally indicated at early stages of kidney disease; nevertheless, with decreased glomerular filtration rate, the pharmacotherapy options change as well as the recommendations for hypolipidemic therapy, particularly in patients with end stage renal disease who are dependent on some form of renal replacement therapy (RRT).